Chest
Clinical InvestigationsSerum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients
Section snippets
Patients
The study population consisted of 60 consecutive patients with advanced histologically proven and previously untreated NSCLC. All patients had a history of smoking, and none of them was affected by autoimmune diseases, inflammatory bowel disease, chronic liver disease, asthma, allergies, or other concomitant diseases capable of interfering with IL-10 assay. Staging was expressed according to TNM classification on evaluation of findings of physical examination, routine laboratory tests, and
IL-10 Serum Levels
IL-10 serum levels were significantly higher in cancer patients prior to chemotherapy (17.7 ± 4.4 pg/mL; range, 12 to 35 pg/mL; median, 16.3 pg/mL; 95% CI, 15.0 to 19.5; IQR, 6) with respect to control subjects (9.2 ± 1.5 pg/mL; range 7.4 to 12.0; median 9.0; 95% CI, 8.4 to 10.0; IQR, 1.86; p < 0.05). In addition, IL-10 serum levels were shown to be significantly increased in stage IV patients (n = 32; 21.0 ± 4.2 pg/mL; range, 14 to 35; median, 20.0; 95% CI, 19.5 to 22.5; IQR, 4.1) as compared
Discussion
NSCLC is characterized by an aggressive clinical course and poor response to immunotherapy,24, 25 probably because of the ability of NSCLC cells to produce a wide variety of immunosuppressive factors that may allow escape from immune recognition. A candidate for such a factor in humans is IL-10, a pleiotropic type 2 cytokine with suppressive activity against various aspects of the cellular immunity, namely, inhibition of proinflammatory cytokine production, reduction of antigen-specific
References (29)
- et al.
The host-tumor immune conflict: from immunosuppression to resistance and destruction
Immunol Today
(1997) - et al.
The role of cytokines in cancer
Cytokine Growth Factor Rev
(1996) - et al.
Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed
Surg Oncol
(1996) - et al.
Presence of interleukin (IL)-10 in the ascites of patients with ovarian and other intra-abdominal cancer
Cytokine
(1992) - et al.
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor
Blood
(1993) - et al.
Increased interleukin-10 serum levels in patients with solid tumours
Cancer Lett
(1996) - et al.
On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity
Cell Immunol
(1993) - et al.
Unique and common tumor-specific transplantation antigens of chemically-induced mouse sarcomas
Int J Cancer
(1978) - et al.
Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice
Eur J Immunol
(1991) - et al.
Immunogenicity of a soluble partially purified oncofetal antigen from murine fibrosarcoma in syngeneic mice
J Biol Response Mod
(1989)
Escape from host-antitumor immunity
Crit Rev Oncog
Immunosuppressive factors in human cancer
Adv Cancer Res
High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours
Br J Cancer
Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues
J Surg Oncol
Cited by (131)
Humoral and Cellular Immune Dysregulation and Lung Cancer
2018, IASLC Thoracic OncologyIdentification of novel cytokine biomarkers of hexanal exposure associated with pulmonary toxicity
2017, Environmental PollutionAmelioration of Hepatotoxicity by Sodium Butyrate Administration in Rats
2022, World's Veterinary Journal